IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.799
AS - Asia 3.260
NA - Nord America 2.406
SA - Sud America 725
AF - Africa 65
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.263
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.288
RU - Federazione Russa 2.261
SG - Singapore 1.110
CN - Cina 1.047
BR - Brasile 593
RO - Romania 339
HK - Hong Kong 335
VN - Vietnam 319
IT - Italia 294
SE - Svezia 258
DE - Germania 172
FR - Francia 150
BD - Bangladesh 118
GB - Regno Unito 102
IN - India 78
AR - Argentina 59
CA - Canada 55
FI - Finlandia 54
IQ - Iraq 39
ID - Indonesia 36
MX - Messico 36
AT - Austria 34
PL - Polonia 30
TR - Turchia 28
JP - Giappone 26
ZA - Sudafrica 25
NL - Olanda 23
ES - Italia 21
EC - Ecuador 20
CO - Colombia 15
IE - Irlanda 15
PK - Pakistan 15
MY - Malesia 14
PH - Filippine 13
SA - Arabia Saudita 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 10
LT - Lituania 10
NP - Nepal 10
TN - Tunisia 10
VE - Venezuela 10
CL - Cile 7
CZ - Repubblica Ceca 7
UA - Ucraina 7
DO - Repubblica Dominicana 6
MA - Marocco 6
PE - Perù 6
PY - Paraguay 6
UY - Uruguay 6
AU - Australia 5
BE - Belgio 5
KE - Kenya 5
OM - Oman 5
AZ - Azerbaigian 4
BB - Barbados 4
DZ - Algeria 4
HN - Honduras 4
IL - Israele 4
SV - El Salvador 4
BH - Bahrain 3
CI - Costa d'Avorio 3
NG - Nigeria 3
NI - Nicaragua 3
PT - Portogallo 3
TH - Thailandia 3
CH - Svizzera 2
EU - Europa 2
GE - Georgia 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
MD - Moldavia 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
UG - Uganda 2
AL - Albania 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GY - Guiana 1
HR - Croazia 1
JO - Giordania 1
KI - Kiribati 1
KR - Corea 1
LB - Libano 1
LY - Libia 1
MT - Malta 1
NO - Norvegia 1
QA - Qatar 1
SI - Slovenia 1
Totale 10.259
Salva come PNG Salva come JPEG
Città #
Singapore 544
Moscow 455
Dallas 343
Hong Kong 331
Ashburn 312
San Jose 301
New York 173
Shanghai 164
Beijing 140
Hefei 140
Lauterbourg 121
Ho Chi Minh City 107
Lawrence 95
Princeton 95
Milan 80
Los Angeles 77
Hanoi 76
Munich 55
São Paulo 47
Boardman 44
Nuremberg 42
Orem 41
Helsinki 34
Denver 32
Santa Clara 32
Warsaw 29
Chennai 26
Tokyo 26
London 24
Guangzhou 23
Montreal 21
Frankfurt am Main 20
Brooklyn 19
Da Nang 19
Houston 18
Vienna 18
Atlanta 17
Manchester 17
Baghdad 16
Dublin 16
Stockholm 16
Poplar 15
Rome 15
Council Bluffs 14
Shenzhen 14
Toronto 14
Brasília 13
Johannesburg 13
Rio de Janeiro 13
Amsterdam 12
Ankara 12
Curitiba 12
Falkenstein 12
Phoenix 12
Seattle 12
Turku 12
Washington 12
Biên Hòa 11
Buffalo 11
Chicago 11
Mexico City 11
Tashkent 11
Barnet 9
Guayaquil 9
Haiphong 9
Belo Horizonte 8
Charlotte 8
Kuala Lumpur 8
Pietra Ligure 8
Porto Alegre 8
Pune 8
Querétaro 8
Sorocaba 8
Boston 7
Monza 7
San Francisco 7
Goiânia 6
Hải Dương 6
Lappeenranta 6
Madrid 6
Mumbai 6
New Delhi 6
Quanzhou 6
Salvador 6
Brussels 5
Buenos Aires 5
Campinas 5
City of London 5
Columbus 5
Erbil 5
Ha Long 5
Hangzhou 5
Istanbul 5
Jakarta 5
Las Vegas 5
Montevideo 5
Ottawa 5
Pisa 5
Quezon City 5
Saint Louis 5
Totale 4.708
Salva come PNG Salva come JPEG
Nome #
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 250
Monkeypox in a patient with undifferentiated connective tissue disease 250
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 206
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 177
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 167
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 141
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 125
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 121
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 117
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 114
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 113
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 113
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 111
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 111
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 111
Achieving virological control in pan-resistant HIV-1 infection: A case series 110
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 106
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 105
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 104
Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients 103
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 103
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 103
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 101
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 100
Bictegravir 100
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 97
Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience 96
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 95
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 93
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 91
Disseminated Mycobacterium chimaera infection favoring the development of Kaposi’s sarcoma: a case report 91
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 91
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 91
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 91
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 90
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 89
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 88
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 88
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 86
Inflammation burden score in multidrug-resistant HIV-1 infection 86
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 85
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting 85
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 85
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 83
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 83
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 83
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 82
All-Cause Mortality in People With Four-Class Drug-Resistant Human Immunodeficiency Virus: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 81
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 81
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 81
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 80
Darunavir for the treatment of HIV infection 76
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 75
Addressing late HIV presentation: the current knowledge and unmet needs 72
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 72
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 72
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 70
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 70
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 69
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 69
Is shorter duration of antibiotic treatment feasible in patients with cardiac implantable electronic device infections undergoing device removal? A propensity-adjusted analysis of a 10-year retrospective cohort 69
An evaluation of cabotegravir for HIV treatment and prevention 68
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 68
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 67
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 67
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 67
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 66
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 66
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 65
Cervical cancer risk in women living with HIV across four continents: A multicohort study 64
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 64
Immune recovery and T cell subset analysis during effective treatment with maraviroc 60
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 60
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 60
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 59
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 59
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 59
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 58
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 58
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 58
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 58
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 58
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 56
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 56
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 55
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 55
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 55
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. 54
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 54
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 54
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 54
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 53
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 53
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 53
Influence of gender in predicting CCR5 coreceptor usage 53
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests" 51
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study 51
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 51
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 51
Impact of analytical treatment interruption on burden and diversification of hiv peripheral reservoir: A pilot study 51
Totale 8.517
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.317
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202278 0 0 0 18 9 9 2 13 7 4 9 7
2022/2023494 206 103 28 4 8 42 43 36 19 2 1 2
2023/2024463 11 18 81 31 49 121 6 43 1 4 27 71
2024/20252.159 194 25 42 64 89 164 661 167 250 132 114 257
2025/20267.233 523 497 480 903 538 243 615 581 1.941 448 280 184
Totale 10.519